A retrospective chart review of UK patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab.

ABSTRACT:

Background

There is limited real-world evidence regarding patients with intermediate/poor-risk advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (NIVO+IPI) in England. This study aimed to describe characteristics, treatment patterns, and efficacy outcomes in these patients.

Methods

A retrospective chart review of medical records in patients with aRCC receiving NIVO+IPI at any line of therapy between 5 April 2019 and 1 April 2022 in five sites across England was conducted. Data were analyzed descriptively overall, in patients with and without NIVO maintenance after NIVO+IPI initiation, and by prior nephrectomy status.

Results

In total, 128 patients (mean age 60.7 years [standard deviation 10.1], 71.1% male) were eligible; most received first-line

SUBMITTER: Geldart T 

PROVIDER: S-EPMC12758230 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature